Alnylam Pharmaceuticals
ALNY
#561
Rank
ยฃ33.03 B
Marketcap
ยฃ249.13
Share price
-0.94%
Change (1 day)
25.15%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2025 : ยฃ0.94 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ0.94 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2025-12-31ยฃ0.94 B-8.09%
2024-12-31ยฃ1.03 B0.79%
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B47.66%
2021-12-31ยฃ0.73 B93.28%
2020-12-31ยฃ0.38 B65.03%
2019-12-31ยฃ0.23 B880.35%
2018-12-31ยฃ23.63 M6.47%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.4 M-27.07%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.33%
2004-12-31ยฃ3.75 M260.93%
2003-12-31ยฃ1.03 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novartis
NVS
ยฃ26.21 B 2,667.23%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ18.91 B 1,897.14%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ2.00 B 111.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ0.92 B-2.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
ยฃ1.03 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.29 B-69.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ12.66 B 1,237.15%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.23 B-75.53%๐Ÿ‡บ๐Ÿ‡ธ USA